Serum nitric oxide (NO) levels in systemic sclerosis patients: Correlation between NO levels and clinical features

Clinical and Experimental Immunology

Volumn 134, Issue 3, 2003, Pages 538-544

  Takagi, K ^a   Kawaguchi, Y ^a   Hara, M ^a   Sugiura, T ^a   Harigai, M ^a   Kamatani, N ^a  

^a TOKYO WOMEN'S MEDICAL UNIVERSITY   (Japan)

Author keywords

Fibroblasts; Fibrosis; Nitric oxide; Systemic sclerosis

Indexed keywords

ENDOTHELIN 1; ENDOTHELIUM DERIVED RELAXING FACTOR; MESSENGER RNA; NITRIC OXIDE; NITRIC OXIDE SYNTHASE;

ADULT; ARTICLE; BLOOD LEVEL; BLOOD VESSEL INJURY; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE DURATION; FEMALE; FIBROSING ALVEOLITIS; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKIN FIBROBLAST; STATISTICAL ANALYSIS; SYSTEMIC SCLEROSIS; VOLUNTEER;

ADOLESCENT; ADULT; AGED; CASE-CONTROL STUDIES; CELLS, CULTURED; FEMALE; FIBROBLASTS; HUMANS; IMMUNOHISTOCHEMISTRY; MALE; MIDDLE AGED; NITRIC OXIDE; NITRIC OXIDE SYNTHASE; PULMONARY FIBROSIS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; SCLERODERMA, SYSTEMIC; SKIN; STATISTICS, NONPARAMETRIC;

EID: 0346121313     PISSN: 00099104     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2003.02320.x     Document Type: Article

References (40)

1. Medsger TA Jr. Systemic sclerosis (scleroderma): clinical aspects. In: Koopman, WJ, ed. Arthritis and allied conditions, 13th edn Philadelphia: Lippincott, Williams & Wilkins, 2001:1562-89.
2. Abraham DJ, Shiwen X, Black CM, Sa S, Xu Y, Leask A. Tumor necrosis factor alpha suppresses the induction of connective tissue growth factor by transforming growth factor-beta in normal and scleroderma fibroblasts. J Biol Chem 2000; 275:15220-5.
3. Alecu M, Geleriu L, Coman G, Galatescu L. The interleukin-1, interleukin-2, interleukin-6 and tumour necrosis factor alpha serological levels in localised and systemic sclerosis. Rom J Intern Med 1998; 36:251-9.
4. Kadono T, Kikuchi K, Ihn H, Takehara K, Tamaki K. Increased production of interleukin 6 and interleukin 8 in scleroderma fibroblasts. J Rheumatol 1998; 25:296-301.
5. Kawaguchi Y, Harigai M, Hara M et al. Increased interleukin 1 receptor, type I, at messenger RNA and protein level in skin fibroblasts from patients with systemic sclerosis. Biochem Biophys Res Commun 1992; 184:1504-10.
6. Cotton SA, Herrick AL, Jayson MI, Freemont AJ. Endothelial expression of nitric oxide synthases and nitrotyrosine in systemic sclerosis skin. J Pathol 1999; 189:273-8.
7. Kawaguchi Y, Suzuki K, Hara M et al. Increased endothelin-1 production in fibroblasts derived from patients with systemic sclerosis. Ann Rheum Dis 1994; 53:506-10.
8. Palmer RM, Ferrige AG, Moncada S. Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 1987; 327:524-6.
9. Palmer RM, Ashton DS, Moncada S. Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988; 333:664-6.
10. Forstermann U, Gath I, Schwarz P, Closs EI, Kleinert H. Isoforms of nitric oxide synthase. Properties, cellular distribution and expressional control. Biochem Pharmacol 1995; 50:1321-32.
11. Chang CI, Liao JC, Kuo L. Macrophage arginase promotes tumor cell growth and suppresses nitric oxide-mediated tumor cytotoxicity. Cancer Res 2001; 61:1100-6.
12. Burnett T, Pung A, Bertram JS, Cooney RV. The role of nitric oxide in neoplastic transformation of C3H 10T1/2 embryonic fibroblasts. Carcinogenesis 2000; 21:1989-95.
13. Farrell AJ, Blake DR, Palmer RM, Moncada S. Increased concentrations of nitrate in synovial fluid and serum samples suggest increased nitric oxide synthesis in rheumatic diseases. Ann Rheum Dis 1992; 51:1219-22.
14. Liu JS, Zhao ML, Brosnan CF, Lee SC. Expression of inducible nitric oxide synthase and nitrotyrosine in multiple sclerosis lesions. Am J Pathol 2001; 158:2057-66.
15. Kahaleh BM, Pan-Sheng F, Cerinic MM, Stefanovic Racic M, Ignarro L. Study of endothelial dependent relaxation in scleroderma [Abstract]. Arthritis Rheum 1993; 36:S180.
16. Allanore Y, Borderie D, Hilliquin P et al. Low levels of nitric oxide (NO) in systemic sclerosis: inducible NO synthase production is decreased in cultured peripheral blood monocyte/macrophage cells. Rheumatology 2001; 40:1089-96.
17. Yamamoto T, Katayama I, Nishioka K. Nitric oxide production and inducible nitric oxide synthase expression in systemic sclerosis. J Rheumatol 1998; 25:314-7.
18. Andersen GN, Caidahl K, Kazzam E et al. Correlation between increased nitric oxide production and markers of endothelial activation in systemic sclerosis: findings with the soluble adhesion molecules E-selectin, intercellular adhesion molecule 1, and vascular cell adhesion molecule 1. Arthritis Rheum 2000; 43:1085-93.
19. Sud A, Khullar M, Wanchu A, Bambery P. Increased nitric oxide production in patients with systemic sclerosis. Nitric Oxide 2000; 4:615-9.
20. Subcommittee for Scleroderma Criteria of the American Rheumatism Association Diagnostic and Therapeutic Criteria Committee. Preliminary criteria for the classification of systemic sclerosis (scleroderma). Arthritis Rheum 1980; 23:581-90.
21. LeRoy EC, Black C, Fleischmajer R et al. Scleroderma (systemic sclerosis): classification subsets and pathogenesis. J Rheumatol 1988; 15;202-5.
22. Gauldie J, Jordana M, Cox G. Cytokines and pulmonary fibrosis. Thorax 1993; 48:931-5.
23. Bolster MB, Silver RM. Assessment and management of scleroderma lung disease. Curr Opin Rheumatol 1999; 11:508-13.
24. Rolla G, Colagrande P, Scappaticci E et al. Exhaled nitric oxide in systemic sclerosis: relationships with lung involvement and pulmonary hypertension. J Rheumatol 2000; 27:1693-8.
25. Fajac I, Kahan A, Menkes CJ et al. Increased nitric oxide in exhaled air in patients with systemic sclerosis. Clin Exp Rheumatol 1998; 16:547-52.
26. Paredi P, Kharitonov SA, Loukides S, Pantelidis P, du Bois RM, Barnes PJ. Exhaled nitric oxide is increased in active fibrosing alveolitis. Chest 1999; 115:1352-6.
27. Moodley YP, Lalloo UG. Exhaled nitric oxide is elevated in patients with progressive systemic sclerosis without interstitial lung disease. Chest 2001; 119:1449-54.
28. Nathan C, Xie QW. Regulation of biosynthesis of nitric oxide. J Biol Chem 1994; 269:13725-8.
29. Kawaguchi Y, Hara M, Wright TM. Endogenous IL-1alpha from systemic sclerosis fibroblasts induces IL-6 and PDGF-A. J Clin Invest 1999; 103:1253-60.
30. Feghali CA, Bost KL, Boulware DW, Levy LS. Mechanisms of pathogenesis in scleroderma, I. overproduction of interleukin 6 by fibroblasts cultured from affected skin sites of patients with scleroderma. J Rheumatol 1992; 19:1207-11.
31. Hirata Y, Emori T, Eguchi S et al. Endothelin receptor subtype B mediates synthesis of nitric oxide by cultured bovine endothelial cells. J Clin Invest 1993; 91:1367-73.
32. Rubinstein I, Abassi Z, Coleman R, Milman F, Winaver J, Better OS. Involvement of nitric oxide system in experimental muscle crush injury. J Clin Invest 1998; 101:1325-33.
33. Singh VK, Mehrotra S, Narayan P, Pandey CM, Agarwal SS. Modulation of autoimmune diseases by nitric oxide. Immunol Res 2000; 22:1-19.
34. Gilkeson GS, Mudgett JS, Seldin MF et al. Clinical and serologic manifestations of autoimmune disease in MRL-1pr/1pr mice lacking nitric oxide synthase type 2. J Exp Med 1997; 186:365-73.
35. Steiner L, Kroncke K, Fehsel K, Kolb-Bachofen V. Endothelial cells as cytotoxic effector cells: cytokine-activated rat islet endothelial cells lyse syngeneic islet cells via nitric oxide. Diabetologia 1997; 40:150-5.
36. Kaur H, Halliwell B. Evidence for nitric oxide-mediated oxidative damage in chronic inflammation: nitrotyrosine in serum and synovial fluid from rheumatoid patients. FEBS Lett 1994; 350:9-12.
37. Farrell AJ, Blake DR. Nitric oxide. Ann Rheum Dis 1996; 55:7-20.
38. Mahr S, Neumayer N, Gerhard M, Classen M, Prinz C. IL-1 beta-induced apoptosis in rat gastric enterochromaffin-like cells is mediated by iNOS, NF-kappaB, and Bax protein. Gastroenterol 2000; 118:515-24.
39. Fehsel K, Kroncke KD, Meyer KL, Huber H, Wahn V, Kolb-Bachofen V. Nitric oxide induces apoptosis in mouse thymocytes. J Immunol 1995; 155:2858-65.
40. Sgonc R, Gruschwitz MS, Dietrich H, Recheis H, Gershwin ME, Wick G. Endothelial cell apoptosis is a primary pathogenetic event underlying skin lesions in avian and human scleroderma. J Clin Invest 1996; 98:785-92.